Latest filings (excl ownership)
CT ORDER
Confidential treatment order
15 Jun 23
DEFM14A
Proxy related to merger
5 Jun 23
PREM14A
Preliminary proxy related to merger
26 May 23
DEFA14A
Additional proxy soliciting materials
19 May 23
10-K
2022 FY
Annual report
30 Mar 23
EFFECT
Notice of effectiveness
20 Mar 23
15-12G
Securities registration termination
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
POS AM
Prospectus update (post-effective amendment)
14 Mar 23
25-NSE
Exchange delisting
3 Mar 23
DEFA14A
Additional proxy soliciting materials
25 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Jan 23
DEFA14A
Additional proxy soliciting materials
9 Jan 23
8-K
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
9 Jan 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
14 Nov 22
8-K
Termination of a Material Definitive Agreement
29 Sep 22
NT 10-Q
Notice of late quarterly filing
16 Aug 22
10-Q
2022 Q2
Quarterly report
16 Aug 22
8-K
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
15 Aug 22
8-K
Amendments to Articles of Incorporation or Bylaws
14 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 22
DEFA14A
Additional proxy soliciting materials
23 May 22
8-K
Entry into a Material Definitive Agreement
23 May 22
10-Q
2022 Q1
Quarterly report
10 May 22
8-K
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
10 May 22
DEFA14A
Additional proxy soliciting materials
20 Apr 22
DEF 14A
Definitive proxy
20 Apr 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Apr 22
PRE 14A
Preliminary proxy
8 Apr 22
S-8
Registration of securities for employees
31 Mar 22
10-K
2021 FY
Annual report
31 Mar 22
Latest ownership filings
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
26 May 23
4
Change in insider ownership
26 May 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
9 Feb 23
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
9 Feb 23
SC 13G/A
INCYTE CORP
8 Feb 23
4
DEEPIKA PAKIANATHAN
31 Jan 23
4
Eric Sjogren
25 Jan 23
4
Emil Kuriakose
25 Jan 23
4
Susan Molineaux
25 Jan 23
4
Stephanie Wong
25 Jan 23
4
Christopher Molineaux
25 Jan 23
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
8 Dec 22
4
Change in insider ownership
6 Jul 22
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
6 Jul 22
4
SUZY JONES
3 Jun 22
4
DEEPIKA PAKIANATHAN
3 Jun 22
4
J. Scott Garland
3 Jun 22
4
SUNIL AGARWAL
3 Jun 22
4
Blake Wise
3 Jun 22
4
Keith Orford
3 Jun 22
4
Henry Ward Wolff
3 Jun 22
SC 13D
TAKEDA PHARMACEUTICAL CO LTD
21 Apr 22
3
Initial statement of insider ownership
21 Apr 22
SC 13G
CITADEL ADVISORS LLC
11 Apr 22
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 22
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
10 Feb 22
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
10 Feb 22
SC 13G/A
VANGUARD GROUP INC
9 Feb 22
4
Susan Molineaux
27 Jan 22
4
Stephanie Wong
27 Jan 22
4
Sumita Ray
27 Jan 22
4
Eric Sjogren
27 Jan 22
4
Francesco Parlati
27 Jan 22
4
Christopher Molineaux
27 Jan 22
4
Keith Orford
27 Jan 22
4
Emil Kuriakose
27 Jan 22
4
Francesco Parlati
25 Jan 22
4
Stephanie Wong
25 Jan 22